<DOC>
	<DOCNO>NCT01781026</DOCNO>
	<brief_summary>The purpose trial study activity vemurafenib untreated melanoma brain metastasis harbor B-Raf proto-oncogene , serine/threonine kinase ( BRAF ) mutation amenable stereotactic radiosurgery base size , number lesion location , measure cerebrospinal fluid ( CSF ) level vemurafenib indicator central nervous system penetrance measure level vemurafenib normal brain tissue brain metastases surgical management feasible .</brief_summary>
	<brief_title>Phase 2 Study Neoadjuvant Vemurafenib Melanoma Patients With Untreated Brain Metastases</brief_title>
	<detailed_description>This phase II single arm study . After establish eligibility , include least one lesion amenable immediate stereotactic radiosurgery ( SRS ) surgical resection base size location OR four lesion , patient begin therapy vemurafenib 960 mg PO BID continuous dose . Any lesion deem need amenable urgent local therapy treat prior initiation vemurafenib , provide patient least one untreated evaluable lesion . An MRI brain obtain 4 week vemurafenib therapy . If CNS index lesion ( ) stable shrinking , additional 4 week vemurafenib give goal provide definitive local therapy 8 week . If lesion grow 4 week , depend size concern symptom evolution , PIs either continue vemurafenib 4 additional week provide definitive local regional therapy 4 week mark form surgery , Laser Induced Thermal Therapy ( LITT ) , Stereotactic Radiosurgery ( SRS ) Whole Brain Radiation Therapy ( WBRT ) . If lesion become symptomatic time , local therapy administer , patient remain study provide additional untreated brain metastasis . If patient receives LITT surgical resection , biopsy sample send sponsor measurement vemurafenib level tumor normal brain parenchyma . Levels pERK , surrogate vemurafenib activity , measure tumor sample . Vemurafenib hold morning radiation restart following day . Vemurafenib dose hold surgery . All patient ask lumbar puncture 4 week vemurafenib therapy . The next MRI brain obtain week 8 every 8 week , along body CT PET/CT scan . If patient overall shrinkage stable disease CNS lesion ( ) , individual cerebral metastasis enlarges , local therapy do study time necessary . Patients continue vemurafenib overall disease progression either CNS lesion ( ) systemic metastasis determine modify MacDonald criterion ( cerebral lesion ( ) ) RECIST criterion ( systemic disease ) , toxicities preclude continue study drug , withdrawal study , development severe illness , neurologic systemic complication follow local therapy lesion , termination study , death . Dose reduction toxicity allow .</detailed_description>
	<mesh_term>Melanoma</mesh_term>
	<criteria>Biopsy proven metastatic melanoma Braf V600E V600K mutation . Untreated brain metastasis At least one cerebral metastasis amenable stereotactic radiosurgery ( SRS ) surgical resection base size location OR four lesion Patients may symptomatic time enrollment , necessary local therapy and/or corticosteroid , patient asymptomatic vemurafenib initiate . Age &gt; 18 Adequate organ function ECOG performance status &lt; 3 No prior therapy selective inhibitor mutate BRAF ; prior therapy must administer least 4 week administration vemurafenib Life expectancy least 3 month Understanding willingness consent The use corticosteroid control cerebral edema treat symptom allow A history whole brain radiotherapy brain metastasis allow , stable lesion present time WBRT NOT consider evaluable . A minimum 1 week break require prior WBRT initiation vemurafenib therapy . Presence leptomeningeal disease base positive CSF cytology . History presence clinically significant ventricular atrial dysrhythmias â‰¥ Grade 2 ( NCI CTCAE , v4.0 ) , Corrected QT ( QTc ) interval &gt; 450 ms baseline history congenital long QT syndrome Uncontrolled medical illness , uncontrolled infection , congestive heart failure MI within 2 month . Second active , untreated malignancy , likely result patient 's demise prior death uncontrolled melanoma CNS metastases . This determined case case basis PIs . Unwillingness undergo monitoring secondary malignancy include clinical dermatologic examination head neck examination serial CT scan .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>B-raf V600E</keyword>
	<keyword>V600K mutation</keyword>
	<keyword>metastatic melanoma</keyword>
</DOC>